Abobotulinumtoxina
Dysport (abobotulinumtoxina) is an unknown pharmaceutical. Abobotulinumtoxina was first approved as Dysport on 2009-04-29. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and hyperhidrosis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Dysport
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dysport | Biologic Licensing Application | 2023-09-30 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
abobotulinumtoxina, Dysport, Ipsen Biopharm Limited | |||
| 2123-07-29 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J0586 | Injection, abobotulinumtoxina, 5 units |
Clinical
Clinical Trials
1129 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 7 | 14 | 21 | 19 | 24 | 80 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 4 | 10 | 20 | 15 | 22 | 67 |
| Cerebral palsy | D002547 | — | G80 | 3 | 10 | 20 | 4 | 20 | 53 |
| Torticollis | D014103 | HP_0000473 | F45.8 | 5 | 11 | 11 | 10 | 14 | 49 |
| Muscle spasticity | D009128 | HP_0001257 | — | 1 | 5 | 11 | 10 | 16 | 43 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 2 | 8 | 10 | 9 | 9 | 36 |
| Urinary incontinence | D014549 | HP_0000020 | R32 | 1 | 5 | 11 | 6 | 7 | 28 |
| Blepharospasm | D001764 | — | G24.5 | 1 | 4 | 6 | 4 | 7 | 20 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | 3 | 2 | 6 | 6 | 3 | 18 |
| Hyperhidrosis | D006945 | HP_0000975 | — | 3 | 3 | 4 | 4 | 4 | 18 |
Show 83 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sialorrhea | D012798 | HP_0002307 | K11.7 | — | 5 | 7 | — | 2 | 11 |
| Plantar fasciitis | D036981 | EFO_1001909 | M72.2 | 1 | 6 | 2 | — | 2 | 9 |
| Tennis elbow | D013716 | EFO_1001896 | M77.1 | — | — | 4 | — | 3 | 7 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 3 | 4 | — | — | 6 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | 1 | 2 | 2 | — | 1 | 6 |
| Vulvodynia | D056650 | — | N94.81 | — | 1 | 3 | — | 1 | 5 |
| Temporomandibular joint disorders | D013705 | — | M26.6 | 1 | 2 | 2 | — | 1 | 5 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | 4 | 2 | — | — | 4 |
| Paresis | D010291 | HP_0001269 | — | — | 2 | 1 | — | 1 | 4 |
| Headache | D006261 | HP_0002315 | R51 | — | — | 2 | — | 2 | 4 |
Show 35 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Essential tremor | D020329 | EFO_0003108 | G25.0 | — | 3 | — | — | 2 | 5 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | 1 | 2 | — | — | 2 | 5 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | 2 | 3 |
| Neck pain | D019547 | HP_0030833 | M54.2 | 2 | 1 | — | — | 1 | 3 |
| Carpal tunnel syndrome | D002349 | EFO_0004143 | G56.0 | — | 3 | — | — | — | 3 |
| Contracture | D003286 | HP_0001371 | M62.4 | — | 1 | — | — | 2 | 3 |
| Abdominal hernia | D046449 | — | K46 | — | 1 | — | — | 1 | 2 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | — | — | 2 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | 2 | — | — | — | 2 |
| Chronic disease | D002908 | — | — | — | 2 | — | — | — | 2 |
Show 48 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhagic stroke | D000083302 | — | — | 1 | — | — | — | 2 | 3 |
| Skin abnormalities | D012868 | HP_0000951 | Q82.9 | 1 | — | — | — | 1 | 2 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 2 | — | — | — | — | 2 |
| Internal carotid artery dissection | D020215 | — | — | 1 | — | — | — | — | 1 |
| Vertebral artery dissection | D020217 | — | I77.74 | 1 | — | — | — | — | 1 |
| Affect | D000339 | — | — | 1 | — | — | — | — | 1 |
| Gingival overgrowth | D019214 | — | K06.1 | 1 | — | — | — | — | 1 |
| Treatment-resistant depressive disorder | D061218 | — | — | 1 | — | — | — | — | 1 |
| Complex regional pain syndromes | D020918 | EFO_1001998 | — | 1 | — | — | — | — | 1 |
| Secondary headache disorders | D051271 | — | — | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Equinus deformity | D004863 | — | — | — | — | — | — | 3 | 3 |
| Esophageal motility disorders | D015154 | — | K22.4 | — | — | — | — | 2 | 2 |
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 2 | 2 |
| Diffuse esophageal spasm | D015155 | EFO_1001785 | K22.4 | — | — | — | — | 2 | 2 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | — | — | — | 2 | 2 |
| Constipation | D003248 | HP_0002019 | K59.0 | — | — | — | — | 2 | 2 |
| Pancreatic fistula | D010185 | — | — | — | — | — | — | 1 | 1 |
| Treatment outcome | D016896 | — | — | — | — | — | — | 1 | 1 |
| Muscle tonus | D009129 | — | — | — | — | — | — | 1 | 1 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 1 | 1 |
Show 30 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Abobotulinumtoxina |
| INN | — |
| Description | Botulinum toxin, or botulinum neurotoxin (commonly called botox), is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes. Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent.
|
| Classification | Neurotoxin |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >2VU9:A|BOTULINUM NEUROTOXIN A HEAVY CHAIN
MGSSHHHHHHSSGLVPRGSHMDTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIV
YNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINR
WIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSN
SGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNI
VRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFH
QFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPLQ |
Identifiers
| PDB | 2G7P, 2VU9, 2VUA, 3BTA, 3DDA, 3DDB, 3DS9, 3DSE, 3FUO, 3K3Q, 3QIX, 3QIY, 3QIZ, 3QJ0, 3QW5, 3QW6, 3QW7, 3QW8, 3ZUR, 3ZUS, 4EJ5, 4EL4, 4ELC, 4HEV, 4IQP, 4JRA, 4KS6, 4KTX, 4KUF, 4ZJX, 5JLV, 5JMC, 5L21, 5MK6, 5MK7, 5MOY, 5TPB, 5TPC, 5V8P, 5V8R, 5V8U, 5VGV, 5VGX, 6DKK, 6ES1, 6MHJ, 6XCB, 6XCC, 6XCD, 6XCE, 6XCF, 7N18 |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108570 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00083 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,729 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dysport
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,991 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use